

# The progress in diagnosis and treatment of exosomes and micrornas on epileptic CO...

[Health & Medicine](#)



## Introduction

Epilepsy is a clinical syndrome of highly synchronous abnormal discharge of brain neurons caused by many causes ( [1](#) ). About 65 million people worldwide suffer from epilepsy which is the common nervous system disease ( [2](#) ). The occurrence of epileptic diseases will not only cause health problems, but also have a serious impact on patients' mood, occupation, life and overall quality of life. Epilepsy patients have a large psychological pressure and are often associated with various mental disorders, especially depression. Depression is the most common mental complications in epileptic patients, with population—based studies suggesting that one in three epilepsy patients may suffer from depression ( [3](#), [4](#) ). The disability rate and mortality of epilepsy accompanied by depression are higher than that of non-depression group, and the effect of antiepileptic drugs and surgery is worse than that of non-depression group ( [5](#) ). Therefore, the diagnosis and treatment of epileptic co-depression is urgent. Nowadays, there are more and more researches linking the pathophysiology of seizures and depression to exosomes and microRNAs ( [6](#) - [8](#) ).

Exosomes are a class of membrane lipid vesicles with a diameter of between 40 and 100 nm ( [9](#) ), containing messenger RNAs, microRNAs, proteins, and liposomes, which can involve in cell-to-cell communication and targeting cells ( [10](#) ). Exosomes can be widely extracted in the blood, urine, cerebrospinal fluid, and other bodily fluids ( [11](#), [12](#) ). And the number and composition of exosomal miRNAs are different between epileptic or depressive patients and healthy individuals ( [13](#) ). MicroRNAs are a type of

highly conservative with a length of about 22 nucleotides noncoding single-stranded RNAs encoded by an endogenous gene ( [14](#) ), which can participate in the regulation of gene expression by that a single miRNA target hundreds of mRNAs. And microRNAs can be excreted by exosomes which offer a stable environment for secreted microRNAs ( [15](#) ). The exosome containing microRNAs flows out of the cerebrospinal fluid and can cross the blood-brain barrier, so that a biological marker representing a brain disease can be extracted in the peripheral blood ( [16](#) ), such as epilepsy ( [17](#) ) and depression. In addition, the pathological mechanisms of epilepsy and depression are complex and may involve blood-brain barrier injury, central nervous inflammatory response, demyelinating lesions, nerve cell injury, etc ( [18](#), [19](#) ). Exosomes, as a new type of cell communication vector, can participate in the regulation of central nervous system neuroinflammation by specific binding with target cells of nervous system, reduce neuronal loss and so on ( [20](#) ). For example, researchers treated pilocarpine-induced epilepsy models with stem cell-derived exosomes and found that this exosomes alleviated inflammation and improved status epilepticus-induced learning and memory impairment in mice by targeting hippocampal astrocytes ( [11](#) ).

Therefore, we herein review the development of exosomes and microRNAs in the field of epilepsy and depression, as well as the current clinical diagnosis and treatment in this neighborhood. And the objective of this paper is to explain the prospect of exosomes and microRNAs in the diagnosis and treatment of epilepsy comorbid depression, and to seek new ideas for the clinical diagnosis and treatment of epilepsy comorbid depression.

<https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>

## The Current Clinical Diagnosis and Treatment of Epilepsy Comorbid Depression

Epilepsy is a central nervous system disease, chronic brain disease characterized by transient central nervous system dysfunction caused by abnormal discharge of brain neurons. There has been a problem with the definition of epilepsy, which has recently been elaborated by ILAE as a disease of the brain defined by any of the following conditions: 1) At least two unprovoked (or reflex) seizures occurring > 24 h apart; 2) one unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years; 3) diagnosis of an epilepsy syndrome ( [2](#) ). And the new definition is designed to increase clinical operability to ensure diagnostic accuracy ( [2](#) ). According to statistics, the prevalence of epilepsy in developed countries accounts for 0.5%–1% of the total population, and is higher in developing countries ( [21](#) ). Domestic epidemiological data show that the total prevalence of epilepsy in China is 7%, and it increases at the rate of 400,000 people per year ( [22](#) ). Depression has become a common and serious comorbidity in epilepsy patients, and data show that the prevalence of depression in epilepsy patients reaches 22.9% ( [23](#) ), which is higher than the prevalence of 6.1%–9.5% in the general population ( [24](#) ). For children with epilepsy, the prevalence of this comorbidity is even more frightening, reaching 21% to 60%, 3–6 times higher than for the general population ( [25](#), [26](#) ). Epilepsy comorbid depression further exacerbates seizures and has a far greater adverse effect on their quality of life than seizure frequency and severity ( [27](#) ). At present, there is no systematic, standardized diagnostic criteria for epilepsy comorbidity depression. Its <https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>

clinical diagnosis mainly depends on the Neurological Disorder Depression Inventory for Epilepsy (NDDI-E) as a rapid and effective clinical detection, but the characteristics of the self-assessment of the scale may affect the evaluation results owe to the patient's sense of disease shame ( [28](#) ). While in comorbidity treatment, some antiepileptic drugs (such as phenobarbital) that reduce the levels of serotonin and norepinephrine in the synapse can lead to depressive episodes ( [29](#) ), and SSRIs (Selective serotonin reuptake inhibitors) antidepressants can increase the risk of seizures ( [30](#) ). In addition, In addition, due to the complexity and heterogeneity of the etiology of epilepsy, some patients with seizures are difficult to control, and about 30% to 50% of patients with refractory epilepsy are accompanied by depression ( [31](#) ). Therefore, the diagnosis and treatment of epilepsy comorbid depression needs further exploration.

## **MicroRNAs, Biomarkers for Epilepsy and Depression, Facilitate the Prognosis of Epileptic Comorbidity Depression**

### **MicroRNAs as Potential Diagnostic Biomarkers for Epilepsy**

The occurrence of epilepsy involves neurotransmitter signals, ion channels, synaptic structures, neuronal death, glial hyperplasia, and inflammation ( [32](#) ). MicroRNAs is a small class of non-coding RNAs, that can regulate gene expression ( [33](#) ). And the regulation by microRNA networks can involve in the development of human brain ( [34](#) ), so the breaking of dynamic balance may lead to neuropathology, such as epilepsy. Raouf et al. did a follow-up study, they performed genome-wide PCR-based and RNA sequencing in plasma from a larger cohort of samples (> 250) from two countries, drawing a conclusion that miR-27a-3p, miR-328-3p and miR-654-3p could be

regarded as potential biomarkers for epilepsy ( [35](#) ). Moreover, these microRNAs levels in exosomes consisted in plasma are higher, that provides the feasibility of these microRNAs as a potential diagnostic marker for epilepsy patients ( [36](#) ). On the other hand, for genetic generalized epilepsies, it may be more connection with microRNAs. Martins-Ferreira et al. found that miR-146a, miR-155, and miR-132 may partake in genetic generalized epilepsies(GGE) epileptogenesis and they reported that the three circulating microRNAs have potential value to be GGE biomarker ( [37](#) ). In particular, the striking up-regulation of miR-132 in epilepsy has been described in several experimental articles ( [38](#) - [40](#) ). Xiang et al. overexpressed miR-132 in the hippocampal neuronal culture model of status epilepticus with transfection technique, they manifested that the overexpression of miR-132 significantly increases the frequency of epileptic discharge in epileptic neurons, that is similar to that miR-132 participates in the postepileptic enhancement of high voltage activated Ca<sup>2+</sup> currents ( [41](#) ). These discoveries suggest that miR-132 may play an epileptic role in the development of epilepsy. However, what's interesting is that miR-132 can be regarded as a negative regulator of transforming growth factor beta 1 (TGF-β1) and cytokine interleukin-1 beta(IL-1β) induced epileptogenic factors ( [39](#) ). And previous studies have found that the activated TGF-β1 encourage epileptogenesis ( [42](#) , [43](#) ). Likewise, the proinflammatory pathway mediated by cytokine interleukin-1 (IL-1β) participates in the occurrence of epilepsy ( [44](#) ). Alyu et al. proposed that IL-1β is associated with epileptic seizures by that it can enhance the ability of astrocytes to release glutamate and reduces glutamate reuptake, thereby increasing the utilization of glutamate

in neuronal synapses and promoting the overexcitability of neurons ( [45](#) ). In conclusion, miR-132 plays an important role in the development of epilepsy, but its regulation mechanism needs further study.

### **MicroRNAs as Potential Diagnostic Biomarkers for Patients With Depression**

Nowadays, the incidence of depression is getting higher and higher, and the disorder of epilepsy with mental disorder is also the majority of the depression. Early detection and early diagnosis are beneficial to the prognosis of depression. More and more studies indicate that many microRNAs express to be abnormal in patients with depression. For example, a standpoint that microRNA-124 can act as a biomarker for depression has been put forward in experiments involving rodents, human postmortem brain, and blood cells of depressed patients ( [46](#), [47](#) ). Roy and Dunbar et al. constructed a CORT-induced depression rats model, they found that the expression of miR-124 was upregulated in PFC, and then the consistent result was validated in post-mortem brain samples of depression patients, moreover, the similar dysregulation of miRNA-124 was detected in peripheral blood serums of depression patients who were psychotropic drug-free for at least one month ( [47](#) ). The maladjustment of hypothalamus-pituitary-adrenal (HPA) axis can increase depression prevalence in epilepsy patients ( [48](#) ), and the sustained overactivity of the HPA axis is a manifestation of the brain's inability to response depression state ( [49](#) ). And the expression of Nr3c1 and Gria4 associated with stress responsive pathway in depression can promote the activity of HPA axis, however micro-124 has inhibitory effect on these two genes ( [46](#) ). Moreover, there is evidence that the overexpression of miR-124 in hippocampus enhanced the adaptability to

depression-like behavior and the decrease of hippocampal miR-124 could boost the sensitivity to depression-like behavior after normal benign mild chronic stress regimen ( [50](#) ). In addition, some scholars compared the expression profile of various microRNA in patients with depression with that in normal subjects, from the results of their comparison, the expression of the microRNA let-7b and let-7c was significantly down-regulated in patients with depression, and let-7c and let-7b participate in regulation for the expression of 27 genes which involved in the PI3k-Akt-mTOR signaling pathway ( [51](#) , [52](#) ). However, one of the 27 genes is the insulin-like growth factor (IGF1) which is a significant over-representation in the regulation of let-7c and let-7b, and which can promote the signal conduction of the brain-derived neurotrophic factor, and can also be combined with the brain-derived neurotrophic factor to induce the anti-depression effect ( [52](#) ). Besides, Gheysarzadeh et al. found that the serum levels of three miRNAs (miR-16, miR-135a, and miR-1202) in patients with depression who were medication-free for at least 2 months before sampling were significantly lower than those in normal subjects, these miRNAs can also be potential biomarkers for depression ( [53](#) ). And what calls for special attention is that microRNAs may be affected by antidepressants, such as mentioned above miR-16 whose important targets cover serotonin transporters, and in mouse model, chronic utilization with the SSRI fluoxetine can increase levels of miR-16 in serotonergic raphe nuclei ( [54](#) ). Similarly, management of acute or chronic SSRI antidepressants in a mouse model of depression can augment miR135a levels in the raphe nuclei ( [55](#) ). Unfortunately, there was no significant difference between miR-16 and miR135a levels in human blood



before and after treatment with SSRI antidepressants ( [55](#) ). Nevertheless, Issler and other researchers measured levels of miR135a in the blood of depression patients after three months of cognitive behavioral therapy (CBT), exposing a prominent up-regulation in miR135a levels after CBT ( [55](#) ). Of course, there is a lot of research on the effect of antidepressant therapy on miRNA expression in depression patients ( [56](#), [57](#) ), for instance, miR124 levels in peripheral blood of depressed human patients decreased significantly after 8 weeks of treatment with various antidepressants ( [58](#) ). In conclusion, it is promising that microRNAs are regarded as biomarkers for the diagnosis of depression or the evaluation of antidepressant treatment.

## **Exosomes Are Expected to Be a Nano-Therapeutic Agent for Depression of Epilepsy**

### **Exosomes Can Regulate Myelin Sheath Formation to Combat Epileptic Depression**

Some people have done a postmortem pathological study on suicidal patients with severe depression, they found that oligodendrocyte density and the expression of oligodendrocyte function related genes are reduced for these patients, and they drew a conclusion for that patients with severe depression put up severe white matter demyelination ( [59](#) - [61](#) ). There are evidences that olig2 can promote the differentiation of oligodendrocyte progenitor cell (OPC) into myelin oligodendrocytes ( [62](#) - [64](#) ). And LINGO-1 is a negative regulator of myelin formation of oligodendrocytes in the central nervous system ( [65](#), [66](#) ). Whereas, a research manifested that Olig2 expression was decreased while LINGO-1 expression for the animal model with spontaneous recurrent epileptic seizures combined depression (SRS-D), and compared to normal group, Olig2 and LINGO-1 expression was no

<https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>

significant difference in the animal model with spontaneous recurrent epileptic seizures combined no depression (SRS-ND) ( [67](#) ). Meanwhile, the SRS-D group detected decreased myelin basic protein (MBP) expression and decreased myelination, likewise, the SRS-ND group had no significant difference with normal group ( [67](#) ). They consider that the demyelination disorder is associated with depression ( [68](#) ) and the demyelination in the epilepsy leads to the occurrence of the combined depression of the epilepsy ( [67](#) ). Fortunately, the exosomes have shown a positive effect in some other demyelinating diseases, exhibiting enhanced myelination and inhibition of demyelination. An animal experiment on the role of exosomes secreted by human mesenchymal stem cells (MSC) in the treatment of multiple sclerosis found that demyelination was reduced in exosome-treated experimental autoimmune encephalomyelitis (EAE) mouse ( [69](#) , [70](#) ). So the exosomes secreted by MSCs have the effect of resistance to demyelination. Besides, myelination is a complex process which is regulated by micro RNAs, such as miR-219 and miR-338 ( [71](#) , [72](#) ). Milbreta et al. applied a scaffolding system which enables sustained non-viral delivery of microRNAs to oligodendrocytes, and they found that the animals treated with miR-219/miR-338 preserved a higher number of Olig2, than the control group ( [73](#) ). They also authenticated scaffold-mediated delivery of miR-219/miR-338 could enhance myelin formation after spinal cord injury (SCI) which can inhibit myelin formation by a phenomenon that MBP expression was more extensive in scaffolds that incorporated miR-219/miR-338 ( [73](#) ). Similarly, maybe transfection of miR-219/miR-338 into synthetic multivalent antibodies retargeted exosome which can control cellular immunity ( [74](#) ) to enhance

axonal remyelination after nerve injuries in the central nervous system (CNS) to treat epileptic depression.

### **Mesenchymal Stem Cell-Derived Exosomes and miR-132 May Treat Epileptic Comorbid Depression by Reducing Inflammation of Central Nervous System**

The occurrence of epilepsy involves complex nervous system responses. The inflammation of the brain can promote the epilepsy, the activity of the seizure can promote the production of the inflammatory molecules, thus affecting the severity of the epilepsy and the frequency of the recurrence ( [75](#), [76](#) ). In the cerebrospinal fluid of the patients with epilepsy, the pro-inflammatory cytokines IL-1 $\beta$  have increased significantly, suggesting that the IL-1 $\beta$  level plays an important role in the occurrence and progression of epilepsy ( [77](#), [78](#) ). What's interesting is that the IL-1 $\beta$  plasma levels in patients with temporal lobe epilepsy and depression are significantly higher than the levels in the people for temporal lobe epilepsy without depression, it has verified that there is positive correlation between IL-1  $\beta$  level and depression ( [79](#) ) owing to that the rise of IL-1 $\beta$  in chronic temporal lobe epilepsy further upregulates Indoleamine 2, 3-dioxygenase1 (IDO1) expression to increase the kynurenine/tryptophan ratio and reduce the serotonin/tryptophan ratio in the hippocampus ( [80](#) ). This also reflects the role of IL-1 $\beta$  in epileptic depression. Besides, the evidence suggests that IL-1 $\beta$  knock-down in the hippocampus can significantly alleviate the memory deficits and anxiety and depression-like behavior of the mice induced by lipopolysaccharide(LPS) may due to eliminates the down-regulation of LPS-induced neuropeptide(VGF) and brain-derived neurotrophic factor(BDNF) ( [81](#) ). These evidences indicate that IL-1 $\beta$  is not only involved in the occurrence

of epilepsy, but also promotes the occurrence of depression in patients with epilepsy. Nevertheless, an experiment on therapeutic effects of mesenchymal stem cell-derived exosomes (MSC-Exos) on retinal detachment found that the expression of IL-1 $\beta$  were significantly reduced after MSC-Exos treatment ( [82](#) ). The anti-inflammatory effects of MSC-Exos were also demonstrated in an animal experiment to improve the prognosis of sepsis syndrome (SS). First, they confirmed that SS causes a severe inflammatory response not only in circulation but also in the brain, leading to severe brain damage, they found that some inflammatory biomarkers (TLR-2, TLR-4, MYD88, IL-1 $\beta$ , TNF- $\alpha$ , NF- $\kappa$ B, and MMP-9) were significantly higher in cerebrospinal fluid from SS animals than control group, and the anomalies of these molecules in circulatory levels and in brain tissue as well as in CSF were observably inhibited by adipose-derived mesenchymal stem cell-derived exosomes ( [83](#) ). The anti-inflammatory effect of MSC-Exos, especially the inhibition of IL-1 $\beta$ , may have a certain treatment prospect for epileptic comorbidity depression. Moreover, exosomes has been considered to be a vector that promotes inter-cell communication and regulates the cell function by delivering proteins, RNA, and other molecular components, with its nature for biocompatibility, stability in the circulation, biological barrier permeability, low immunogenicity, and low toxicity ( [7](#), [84](#) ). And *in vitro* model experiments have shown that overexpression of miR-132 can reduce the expression of IL-1 $\beta$  ( [39](#), [85](#) ). In addition, it was reported that IL-1 $\beta$  could induce disruption of the blood-brain barrier ( [86](#) - [88](#) ). Blood-brain barrier dysfunction is related with epilepsy ( [89](#) ) and the experiment found that the indicator of blood-brain barrier dysfunction ( [90](#) ) (MMP-9 concentration) was

significantly elevated after the seizure ( [91](#), [92](#) ). Similarly, the increased CSF to serum levels of peripheral markers including albumin and urate in depressed patients indicates a compromised blood-brain barrier ( [53](#) ). And the brain endothelium can express high levels of tight junction proteins and adherens junction molecules to ensure the integrity of the blood-brain barrier ( [93](#) ). Yet, exogenous miR-132 can suppress the expression of MMP-9 to protect the integrity of the blood-brain barrier by reducing degradation of tight junction proteins ( [94](#), [95](#) ). From the above, miR-132 can play a certain role in the treatment of epilepsy by anti-inflammatory and protecting the integrity of the blood-brain barrier. An experiment by Teng Ma et al. has used Gene Pulser II system to load miR-132 into exosomes, by that to form the miR-132-overexpressed exosomes nano-therapeutic ( [96](#) ). However, Mateos et al. have testified that miR-132-overexpressing therapy can exacerbate neuronal damage by an experiment that intracerebroventricular injection of an antagomir of miR-132 protected against hippocampal CA3 neuronal death 24 h after seizure ( [38](#) ). The pity is that the author did not consider the later time point after seizure when brain inflammation is more obvious ( [39](#) ). So, the optimal time window is a challenge for the miR-132-overexpressed exosomes nano-therapeutic.

Perhaps, the rational application of exosomes and miR-132 is effective to improve the prognosis of epileptic patients and reduce the incidence of depression.

## **The Application Prospect of the Exosomes as a Nano-Therapeutic Carrier**

Exosomes are formed by such a process that first endosome is took shape though invagination of cell membrane, then the endosome evolves to multivesicular bodies, last multivesicular bodies combine with plasmalemma reducing the release of intraluminal vesicle to extracellular. It carries their contents which contain specific mRNAs, regulatory microRNAs, lipids, cytokines and proteins ( [97](#) - [99](#) ) from the donor cell to the recipient cell for the purpose of altering the function of the target cell ( [100](#) ). Therefore, exosomes play a key role in long-range signal transduction between cells ( [101](#) ). And Exosomes have been reported to have a natural targeting ability based on donor cells owing to their inherent biological activity that they intrinsically express some lipids and cell adhesion molecules and ligands ( [102](#) ). So for their function, Luan et al. proposed that using technique to insert the gene encoding the targeting proteins into the donor cells to make the donor cells secreta a kind of exosomes which contain this proteins ( [102](#) ). For example, Ohno et al. applied exosomes in delivering let-7a miRNA in a targeted manner to breast cancer cells in mice ( [103](#) ). Similarly, combined with the above, using exocrine to deliver miR-219/miR-338 to CNS in a targeted manner may improve epileptic depression. In addition, a lot of efforts have also been made to develop exocrine bodies into carriers of drug transport. A variety of techniques have been reported for loading therapeutic agents which contain microRNA, protein, medicine, etc into the exosomes, and these techniques conclude sonication, extrusion, freeze and thaw cycles, electroporation, incubation with membrane permeabilizers, and click chemistry method for direct conjugation ( [102](#) ). Moreover, exosomes have <https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>

prominent advantages as gene therapy delivery carrier for that they consist of cell membranes with multiple adhesion proteins on the surface ( [104](#) ). Besides, exosomes can cross major biological barriers such as the blood-brain barrier for their small size and flexibility ( [105](#) ). Compared to other carriers, exosomes are lower toxic because they are naturally secreted vesicles ( [106](#) ), and exosomes are more tolerated in the body for that they are ubiquitous in body fluids ( [107](#) , [108](#) ). Of course, there are some challenges on the treatment of epileptic comorbidity depression in exosomes. The problem of the more accurate purification of exosomes and the mass production of exosomes in clinic still need our efforts ( [109](#) ), not to mention the further exploration of the relationship between exosomes and depression of epilepsy comorbidity.

## **Summary and Perspectives**

At present, epilepsy patients with depression disorder is common, especially those intractable epilepsy, they are mostly accompanied by depression. Fortunately, research on exosomes and microRNAs as a biomarker for epilepsy and depression is becoming more mature. Nevertheless, there is still a long way to apply microRNAs to the clinic. The detection of microRNAs in peripheral blood is more convenient than that in CSF in the clinical, but this ignores a problem whether these differences can really represent brain-derived genetic alterations. Maybe, it is a better alternative to measure the change of microRNAs in brain-derived exosomes in peripheral blood. And the techniques for quantifying microRNAs (such as qRT-PCR) need to be improved in terms of cost and speed. In addition, in consideration of a study on the molecular mechanism of the interaction of the depression of the

epilepsy, such for IL-1 $\beta$ , it is promising to use exosomes as carrier in the treatment of epileptic comorbid depression. Moreover, exosomes not only play a potential role in the treatment of epileptic comorbid depression as a carrier, but also have great hope for the treatment of epileptic comorbid depression by exosomes themselves, especially MSC-Exos. However, equally, it remains a challenge that exosomes and microRNAs are applied to treat epilepsy comorbid depression in clinical. Most of the above studies have been conducted in animal models and *in vitro* experiments, whether these conclusions can be extended to the human body requires more exploration, but it is also an inspiration for seeking new ways to treat epilepsy comorbid depression. And the mechanism of epilepsy comorbidity depression needs to be further studied, and the pharmacodynamics and toxicology of exosomes *in vivo* need to be further explored.

## **Author Contributions**

NW, HZ and JW designed and written this article, NW, HZ, JW, SW, WL, LL, and ZX contributed to collection and analysis of literature. ZX helped with proofreading and revision. All authors read, revised, and approved the final manuscript.

## **Funding**

This research was supported by the grants of National natural science foundation of China (Grant No 81660227) and the Science and Technology Project in Guizhou Province (Grant No. QKHLHZ[2016]NO. 7476).



## Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## References

1. Guerrini R, Marini C, Barba C. Generalized epilepsies. *Handb Clin Neurol* (2019) 161: 3–15. doi: 10.1016/B978-0-444-64142-7.00038-2

[CrossRef Full Text](#) | [Google Scholar](#)

2. Moshé SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. *Lancet* (2015) 385: 884–98. doi: 10.1016/S0140-6736(14)60456-6

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

3. Kanner AM, Schachter SC, Barry JJ, Hesdorffer DC, Mula M, Trimble M, et al. Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. *Epilepsy Behav* (2012) 24: 156–68. doi: 10.1016/j.yebeh.2012.01.007

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

4. Manford M. Recent advances in epilepsy. *J Neurol* (2017) 264: 1811–24. doi: 10.1007/s00415-017-8394-2

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

5. Kanner AM. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? *Lancet Neurol* (2012) 11: 1093–102. doi: 10.1016/S1474-4422(12)70201-6

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

6. Wei ZX, Xie GJ, Mao X, Zou XP, Liao YJ, Liu QS, et al. Exosomes from patients with major depression cause depressive-like behaviors in mice with involvement of miR-139-5p-regulated neurogenesis. *Neuropsychopharmacology* (2020) 45(6): 1050–8. doi: 10.1038/s41386-020-0622-2

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

7. Batool A, Hill TDM, Nguyen NT, Langa E, Diviney M, Mooney C, et al. Altered Biogenesis and MicroRNA Content of Hippocampal Exosomes Following Experimental Status Epilepticus. *Front Neurosci* (2020) 13: 1404–4. doi: 10.3389/fnins.2019.01404

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

8. Gitaí DLG, dos Santos YDR, Upadhya R, Kodali M, Madhu LN, Shetty AK. Extracellular Vesicles in the Forebrain Display Reduced miR-346 and miR-331-3p in a Rat Model of Chronic Temporal Lobe Epilepsy. *Mol Neurobiol* (2020) 57: 1674–87. doi: 10.1007/s12035-019-01797-1

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

9. Karlsen TA, Aae TF, Brinchmann JE. Robust profiling of microRNAs and isomiRs in human plasma exosomes across 46 individuals. *Sci Rep* (2019) 9: 19999–9. doi: 10. 1038/s41598-019-56593-7

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

10. Gurunathan S, Kang M-H, Jeyaraj M, Qasim M, Kim J-H. Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes. *Cells* (2019) 8: 307. doi: 10. 3390/cells8040307

[CrossRef Full Text](#) | [Google Scholar](#)

11. Xian P, Hei Y, Wang R, Wang T, Yang J, Li J, et al. Mesenchymal stem cell-derived exosomes as a nanotherapeutic agent for amelioration of inflammation-induced astrocyte alterations in mice. *Theranostics* (2019) 9: 5956–75. doi: 10. 7150/thno. 33872

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

12. Nolte-'t Hoen E, Cremer T, Gallo RC, Margolis LB. Extracellular vesicles and viruses: Are they close relatives? *Proc Natl Acad Sci U S A* (2016) 113: 9155–61. doi: 10. 1073/pnas. 1605146113

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

13. Zhang J, Li S, Li L, Li M, Guo C, Yao J, et al. Exosome and exosomal microRNA: trafficking, sorting, and function. *Genomics Proteomics Bioinf* (2015) 13: 17–24. doi: 10. 1016/j. gpb. 2015. 02. 001

[CrossRef Full Text](#) | [Google Scholar](#)

<https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>

14. Lu TX, Rothenberg ME. MicroRNA. *J Allergy Clin Immunol* (2018) 141: 1202–7. doi: 10. 1016/j. jaci. 2017. 08. 034

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

15. Barile L, Vassalli G. Exosomes: Therapy delivery tools and biomarkers of diseases. *Pharmacol Ther* (2017) 174: 63–78. doi: 10. 1016/j. pharmthera. 2017. 02. 020

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

16. Reynolds JL, Mahajan SD. Transmigration of Tetraspanin 2 (Tspan2) siRNA Via Microglia Derived Exosomes across the Blood Brain Barrier Modifies the Production of Immune Mediators by Microglia Cells. *J Neuroimmune Pharmacol : Off J Soc Neuroimmune Pharmacol* (2019). undefined: undefined. doi: 10. 1007/s11481-019-09895-6

[CrossRef Full Text](#) | [Google Scholar](#)

17. Pitkänen A, Löscher W, Vezzani A, Becker AJ, Simonato M, Lukasiuk K, et al. Advances in the development of biomarkers for epilepsy. *Lancet Neurol* (2016) 15: 843–56. doi: 10. 1016/S1474-4422(16)00112-5

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

18. Rana A, Musto AE. The role of inflammation in the development of epilepsy. *J Neuroinflamm* (2018) 15: 144. doi: 10. 1186/s12974-018-1192-7

[CrossRef Full Text](#) | [Google Scholar](#)

19. Wyeth M, Nagendran M, Buckmaster PS. Ictal onset sites and  $\gamma$ -aminobutyric acidergic neuron loss in epileptic pilocarpine-treated rats. *Epilepsia* (2020). doi: 10. 1111/epi. 16490

[CrossRef Full Text](#) | [Google Scholar](#)

20. Huang J-H, Yin X-M, Xu Y, Xu C-C, Lin X, Ye F-B, et al. Systemic Administration of Exosomes Released from Mesenchymal Stromal Cells Attenuates Apoptosis, Inflammation, and Promotes Angiogenesis after Spinal Cord Injury in Rats. *J Neurotrauma* (2017) 34: 3388–96. doi: 10. 1089/neu. 2017. 5063

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

21. Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy-a review. *Epilepsy Res* (2009) 85: 31–45. doi: 10. 1016/j. eplepsyres. 2009. 03. 003

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

22. Xue-Ping W, Hai-Jiao W, Li-Na Z, Xu D, Ling L. Risk factors for drug-resistant epilepsy: A systematic review and meta-analysis. *Medicine* (2019) 98: e16402. doi: 10. 1097/MD. 00000000000016402

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

23. Scott AJ, Sharpe L, Hunt C, Gandy M. Anxiety and depressive disorders in people with epilepsy: A meta-analysis. *Epilepsia* (2017) 58: 973–82. doi: 10. 1111/epi. 13769

<https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

24. Cardamone L, Salzberg MR, O'Brien TJ, Jones NC. Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder? *Br J Pharmacol* (2013) 168: 1531-54. doi: 10.1111/bph.12052

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

25. Ott D, Caplan R, Guthrie D, Siddarth P, Komo S, Shields WD, et al. Measures of psychopathology in children with complex partial seizures and primary generalized epilepsy with absence. *J Am Acad Child Adolesc Psychiatry* (2001) 40: 907-14. doi: 10.1097/00004583-200108000-00012

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

26. Ekinci O, Titus JB, Rodopman AA, Berkem M, Trevathan E. Depression and anxiety in children and adolescents with epilepsy: prevalence, risk factors, and treatment. *Epilepsy Behav* (2009) 14: 8-18. doi: 10.1016/j.yebeh.2008.08.015

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

27. Lehrner J, Kalchmayr R, Serles W, Olbrich A, Patarraia E, Aull S, et al. Health-related quality of life (HRQOL), activity of daily living (ADL) and depressive mood disorder in temporal lobe epilepsy patients. *Seizure* (1999) 8: 88-92. doi: 10.1053/seiz.1999.0272

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

28. Gilliam FG, Barry JJ, Hermann BP, Meador KJ, Vahle V, Kanner AM. Rapid detection of major depression in epilepsy: a multicentre study. *Lancet Neurol* (2006) 5: 399–405. doi: 10. 1016/S1474-4422(06)70415-X

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

29. Rajna P. [Effects of antiepileptic drugs on mood of people with epilepsy]. *Ideggyogyaszati Szemle* (2007) 60: 381–91.

[PubMed Abstract](#) | [Google Scholar](#)

30. Chou CC, Yen DJ, Lin YY, Wang YC, Lin CL, Kao CH. Selective Serotonin Reuptake Inhibitors and Poststroke Epilepsy: A Population-Based Nationwide Study. *Mayo Clin Proc* (2017) 92: 193–9. doi: 10. 1016/j. mayocp. 2016. 10. 011

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

31. Gilliam FG, Santos J, Vahle V, Carter J, Brown K, Hecimovic H. Depression in epilepsy: ignoring clinical expression of neuronal network dysfunction? *Epilepsia* (2004) 45(Suppl. 2): 28–33. doi: 10. 1111/j. 0013-9580. 2004. 452005. x

[CrossRef Full Text](#) | [Google Scholar](#)

32. Henshall DC, Hamer HM, Pasterkamp RJ, Goldstein DB, Kjems J, Prehn JHM, et al. MicroRNAs in epilepsy: pathophysiology and clinical utility. *Lancet Neurol* (2016) 15: 1368–76. doi: 10. 1016/S1474-4422(16)30246-0

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

<https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>

33. Bartel DP. Metazoan MicroRNAs. *Cell* (2018) 173: 20–51. doi: 10. 1016/j. cell. 2018. 03. 006

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

34. Nowakowski TJ, Rani N, Golkaram M, Zhou HR, Alvarado B, Huch K, et al. Regulation of cell-type-specific transcriptomes by microRNA networks during human brain development. *Nat Neurosci* (2018) 21: 1784–92. doi: 10. 1038/s41593-018-0265-3

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

35. Raouf R, Bauer S, El Naggari H, Connolly NMC, Brennan GP, Brindley E, et al. Dual-center, dual-platform microRNA profiling identifies potential plasma biomarkers of adult temporal lobe epilepsy. *EBioMedicine* (2018) 38: 127–41. doi: 10. 1016/j. ebiom. 2018. 10. 068

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

36. Upadhyaya D, Shetty AK. Promise of extracellular vesicles for diagnosis and treatment of epilepsy. *Epilepsy Behav* (2019) 106499. doi: 10. 1016/j. yebeh. 2019. 106499

[CrossRef Full Text](#) | [Google Scholar](#)

37. Martins-Ferreira R, Chaves J, Carvalho C, Bettencourt A, Chorão R, Freitas J, et al. Circulating microRNAs as potential biomarkers for genetic generalized epilepsies: a three microRNA panel. *Eur J Neurol* (2019) 27: 660–6. doi: 10. 1111/ene. 14129

<https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>



[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

38. Jimenez-Mateos EM, Bray I, Sanz-Rodriguez A, Engel T, McKiernan RC, Mouri G, et al. miRNA Expression profile after status epilepticus and hippocampal neuroprotection by targeting miR-132. *Am J Pathol* (2011) 179: 2519–32. doi: 10. 1016/j. ajpath. 2011. 07. 036

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

39. Korotkov A, Broekaart DWM, Banchaewa L, Pustjens B, van Scheppingen J, Anink JJ, et al. microRNA-132 is overexpressed in glia in temporal lobe epilepsy and reduces the expression of pro-epileptogenic factors in human cultured astrocytes. *Glia* (2020) 68: 60–75. doi: 10. 1002/glia. 23700

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

40. Korotkov A, Mills JD, Gorter JA, van Vliet EA, Aronica E. Systematic review and meta-analysis of differentially expressed miRNAs in experimental and human temporal lobe epilepsy. *Sci Rep* (2017) 7: 11592–2. doi: 10. 1038/s41598-017-11510-8

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

41. Xiang L, Ren Y, Cai H, Zhao W, Song Y. MicroRNA-132 aggravates epileptiform discharges via suppression of BDNF/TrkB signaling in cultured hippocampal neurons. *Brain Res* (2015) 1622: 484–95. doi: 10. 1016/j. brainres. 2015. 06. 046

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

<https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>

42. Ivens S, Kaufer D, Flores LP, Bechmann I, Zumsteg D, Tomkins O, et al. TGF- $\beta$  receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. *Brain* (2006) 130: 535-47. doi: 10.1093/brain/awl317

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

43. Zhang Y, Zhu W, Yu H, Yu J, Zhang M, Pan X, et al. P2Y4/TSP-1/TGF- $\beta$ 1/pSmad2/3 pathway contributes to acute generalized seizures induced by kainic acid. *Brain Res Bull* (2019) 149: 106-19. doi: 10.1016/j.brainresbull.2019.04.004

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

44. Vezzani A, Baram TZ. New roles for interleukin-1 Beta in the mechanisms of epilepsy. *Epilepsy Curr* (2007) 7: 45-50. doi: 10.1111/j.1535-7511.2007.00165.x

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

45. Alyu F, Dikmen M. Inflammatory aspects of epileptogenesis: contribution of molecular inflammatory mechanisms. *Acta Neuropsychiatr* (2016) 29: 1-16. doi: 10.1017/neu.2016.47

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

46. Dwivedi Y. microRNA-124: a putative therapeutic target and biomarker for major depression. *Expert Opin Ther Targets* (2017) 21: 653-6. doi: 10.1080/14728222.2017.1328501

<https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

47. Roy B, Dunbar M, Shelton RC, Dwivedi Y. Identification of MicroRNA-124-3p as a Putative Epigenetic Signature of Major Depressive Disorder.

*Neuropsychopharmacol : Off Publ Am Coll Neuropsychopharmacol* (2017) 42: 864–75. doi: 10. 1038/npp. 2016. 175

[CrossRef Full Text](#) | [Google Scholar](#)

48. Zobel A, Wellmer J, Schulze-Rauschenbach S, Pfeiffer U, Schnell S, Elger C, et al. Impairment of inhibitory control of the hypothalamic pituitary adrenocortical system in epilepsy. *Eur Arch Psychiatry Clin Neurosci* (2004) 254: 303–11. doi: 10. 1007/s00406-004-0499-9

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

49. Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, Kern N, et al. Combined Dexamethasone/Corticotropin Releasing Hormone Test Predicts Treatment Response in Major Depression—A Potential Biomarker? *Biol Psychiatry* (2007) 62: 47–54. doi: 10. 1016/j. biopsych. 2006. 07. 039

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

50. Higuchi F, Uchida S, Yamagata H, Abe-Higuchi N, Hobara T, Hara K, et al. Hippocampal MicroRNA-124 Enhances Chronic Stress Resilience in Mice. *J Neurosci* (2016) 36: 7253–67. doi: 10. 1523/JNEUROSCI. 0319-16. 2016

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

51. Tavakolizadeh J, Roshanaei K, Salmaninejad A, Yari R, Nahand JS, Sarkarizi HK, et al. MicroRNAs and exosomes in depression: Potential diagnostic biomarkers. *J Cell Biochem* (2018) 119: 3783–97. doi: 10.1002/jcb. 26599

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

52. Gururajan A, Naughton ME, Scott KA, O'Connor RM, Moloney G, Clarke G, et al. MicroRNAs as biomarkers for major depression: a role for let-7b and let-7c. *Transl Psychiatry* (2016) 6: e862. doi: 10.1038/tp.2016.131

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

53. Gheysarzadeh A, Sadeghifard N, Afraidooni L, Pooyan F, Mofid MR, Valadbeigi H, et al. Serum-based microRNA biomarkers for major depression: MiR-16, miR-135a, and miR-1202. *J Res Med Sci : Off J Isfahan Univ Med Sci* (2018) 23: 69–9. doi: 10.4103/jrms.JRMS\_879\_17

[CrossRef Full Text](#) | [Google Scholar](#)

54. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. *Sci (New York N Y)* (2010) 329: 1537–41. doi: 10.1126/science.1193692

[CrossRef Full Text](#) | [Google Scholar](#)

55. Issler O, Haramati S, Paul ED, Maeno H, Navon I, Zwang R, et al. MicroRNA 135 is essential for chronic stress resiliency, antidepressant

<https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>

efficacy, and intact serotonergic activity. *Neuron* (2014) 83: 344–60. doi: 10.1016/j.neuron.2014.05.042

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

56. Enatescu VR, Papava I, Enatescu I, Antonescu M, Anghel A, Seclaman E, et al. Circulating Plasma Micro RNAs in Patients with Major Depressive Disorder Treated with Antidepressants: A Pilot Study. *Psychiatry Invest* (2016) 13: 549–57. doi: 10.4306/pi.2016.13.5.549

[CrossRef Full Text](#) | [Google Scholar](#)

57. Fiori LM, Lopez JP, Richard-Devantoy S, Berlim M, Chachamovich E, Jollant F, et al. Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response. *Int J Neuropsychopharmacol* (2017) 20: 619–23. doi: 10.1093/ijnp/pyx034

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

58. He S, Liu X, Jiang K, Peng D, Hong W, Fang Y, et al. Alterations of microRNA-124 expression in peripheral blood mononuclear cells in pre- and post-treatment patients with major depressive disorder. *J Psychiatr Res* (2016) 78: 65–71. doi: 10.1016/j.jpsychires.2016.03.015

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

59. Tham MW, Woon PS, Sum MY, Lee TS, Sim K. White matter abnormalities in major depression: evidence from post-mortem, neuroimaging and genetic studies. *J Affect Disord* (2011) 132: 26–36. doi: 10.1016/j.jad.2010.09.013

<https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

60. Feinstein A, Magalhaes S, Richard J-F, Audet B, Moore C. The link between multiple sclerosis and depression. *Nat Rev Neurol* (2014) 10: 507–17. doi: 10. 1038/nrneurol. 2014. 139

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

61. Cathomas F, Azzinnari D, Bergamini G, Sigrist H, Buerge M, Hoop V, et al. Oligodendrocyte gene expression is reduced by and influences effects of chronic social stress in mice. *Genes Brain Behav* (2019) 18: e12475. doi: 10. 1111/gbb. 12475

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

62. Wegener A, Deboux C, Bachelin C, Frah M, Kerninon C, Seilhean D, et al. Gain of Olig2 function in oligodendrocyte progenitors promotes remyelination. *Brain* (2015) 138: 120–35. doi: 10. 1093/brain/awu375

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

63. Weider M, Starost LJ, Groll K, Küspert M, Sock E, Wedel M, et al. Nfat/calcineurin signaling promotes oligodendrocyte differentiation and myelination by transcription factor network tuning. *Nat Commun* (2018) 9: 899–9. doi: 10. 1038/s41467-018-03871-z

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

64. Liu Z, Yan M, Liang Y, Liu M, Zhang K, Shao D, et al. Nucleoporin Seh1 Interacts with Olig2/Brd7 to Promote Oligodendrocyte Differentiation and  
<https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>

Myelination. *Neuron* (2019) 102: 587–601. e587. doi: 10. 1016/j. neuron. 2019. 02. 018

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

65. Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, Shao Z, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. *Nat Neurosci* (2005) 8: 745–51. doi: 10. 1038/nn1460

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

66. Wu D, Tang X, Gu L-H, Li X-L, Qi X-Y, Bai F, et al. LINGO-1 antibody ameliorates myelin impairment and spatial memory deficits in the early stage of 5XFAD mice. *CNS Neurosci Ther* (2018) 24: 381–93. doi: 10. 1111/cns. 12809

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

67. Ma T, Li B, Le Y, Xu Y, Wang F, Tian Y, et al. Demyelination contributes to depression comorbidity in a rat model of chronic epilepsy via dysregulation of Olig2/LINGO-1 and disturbance of calcium homeostasis. *Exp Neurol* (2019) 321: 113034. doi: 10. 1016/j. expneurol. 2019. 113034

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

68. Simpson J, Tan H, Otahal P, Taylor B, Ponsonby A-L, Lucas RM, et al. Anxiety, depression and fatigue at 5-year review following CNS demyelination. *Acta Neurolog Scand* (2016) 134: 403–13. doi: 10. 1111/ane. 12554

<https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>

[CrossRef Full Text](#) | [Google Scholar](#)

69. Riazifar M, Mohammadi MR, Pone EJ, Yeri A, Lasser C, Segaliny AI, et al. Stem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders. *ACS Nano* (2019) 13: 6670–88. doi: 10.1021/acsnano.9b01004

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

70. Hosseini Shamili F, Alibolandi M, Rafatpanah H, Abnous K, Mahmoudi M, Kalantari M, et al. Immunomodulatory properties of MSC-derived exosomes armed with high affinity aptamer toward myelin as a platform for reducing multiple sclerosis clinical score. *J Controlled Release* (2019) 299: 149–64. doi: 10.1016/j.jconrel.2019.02.032

[CrossRef Full Text](#) | [Google Scholar](#)

71. Cantone M, Kuspert M, Reiprich S, Lai X, Eberhardt M, Gottle P, et al. A gene regulatory architecture that controls region-independent dynamics of oligodendrocyte differentiation. *Glia* (2019) 67: 825–43. doi: 10.1002/glia.23569

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

72. Wang H, Moyano AL, Ma Z, Deng Y, Lin Y, Zhao C, et al. miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS. *Dev Cell* (2017) 40: 566–582. e565. doi: 10.1016/j.devcel.2017.03.001

<https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>



[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

73. Milbreta U, Lin J, Pinese C, Ong W, Chin JS, Shirahama H, et al. Scaffold-Mediated Sustained, Non-viral Delivery of miR-219/miR-338 Promotes CNS Remyelination. *Mol Ther : J Am Soc Gene Ther* (2019) 27: 411–23. doi: 10.1016/j.ymthe. 2018. 11. 016

[CrossRef Full Text](#) | [Google Scholar](#)

74. Shi X, Cheng Q, Hou T, Han M, Smbatyan G, Lang JE, et al. Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. *Mol Ther* (2020) 28: 536–47. doi: 10.1016/j.ymthe. 2019. 11. 020

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

75. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. *Nat Rev Neurol* (2011) 7: 31–40. doi: 10.1038/nrneurol. 2010. 178

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

76. Yuen AWC, Keezer MR, Sander JW. Epilepsy is a neurological and a systemic disorder. *Epilepsy Behav* (2018) 78: 57–61. doi: 10.1016/j.yebeh. 2017. 10. 010

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

77. Shi L-m, Chen R-j, Zhang H, Jiang C-m, Gong J. Cerebrospinal fluid neuron specific enolase, interleukin-1 $\beta$  and erythropoietin concentrations in children

after seizures. *Child's Nervous System* (2017) 33: 805–11. doi: 10.1007/s00381-017-3359-4

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

78. Dey A, Kang X, Qiu J, Du Y, Jiang J. Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside. *Trends Pharmacol Sci* (2016) 37: 463–84. doi: 10.1016/j.tips.2016.03.001

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

79. Vieira ÉLM, de Oliveira GNM, Lessa JMK, Gonçalves AP, Sander JW, Cendes F, et al. Interleukin-1 $\beta$  plasma levels are associated with depression in temporal lobe epilepsy. *Epilepsy Behav* (2015) 53: 131–4. doi: 10.1016/j.yebeh.2015.09.035

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

80. Xie W, Cai L, Yu Y, Gao L, Xiao L, He Q, et al. Activation of brain indoleamine 2, 3-dioxygenase contributes to epilepsy-associated depressive-like behavior in rats with chronic temporal lobe epilepsy. *J Neuroinflamm* (2014) 11: 41–1. doi: 10.1186/1742-2094-11-41

[CrossRef Full Text](#) | [Google Scholar](#)

81. Li M, Li C, Yu H, Cai X, Shen X, Sun X, et al. Lentivirus-mediated interleukin-1 $\beta$  (IL-1 $\beta$ ) knock-down in the hippocampus alleviates lipopolysaccharide (LPS)-induced memory deficits and anxiety- and

depression-like behaviors in mice. *J Neuroinflamm* (2017) 14: 190-0. doi: 10.1186/s12974-017-0964-9

[CrossRef Full Text](#) | [Google Scholar](#)

82. Ma M, Li B, Zhang M, Zhou L, Yang F, Ma F, et al. Therapeutic effects of mesenchymal stem cell-derived exosomes on retinal detachment. *Exp Eye Res* (2020) 191: 107899. doi: 10.1016/j.exer.2019.107899

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

83. Chang C-L, Chen H-H, Chen K-H, Chiang JY, Li Y-C, Lin H-S, et al. Adipose-derived mesenchymal stem cell-derived exosomes markedly protected the brain against sepsis syndrome induced injury in rat. *Am J Trans Res* (2019) 11: 3955-71.

[Google Scholar](#)

84. Wu P, Zhang B, Shi H, Qian H, Xu W. MSC-exosome: A novel cell-free therapy for cutaneous regeneration. *Cytotherapy* (2018) 20: 291-301. doi: 10.1016/j.jcyt.2017.11.002

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

85. Che F, Du H, Zhang W, Cheng Z, Tong Y. MicroRNA-132 modifies angiogenesis in patients with ischemic cerebrovascular disease by suppressing the NFkappaB and VEGF pathway. *Mol Med Rep* (2018) 17: 2724-30. doi: 10.3892/mmr.2017.8138

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

<https://assignbuster.com/the-progress-in-diagnosis-and-treatment-of-exosomes-and-micrnas-on-epileptic-comorbidity-depression/>

86. Wang Y, Jin S, Sonobe Y, Cheng Y, Horiuchi H, Parajuli B, et al. Interleukin-1 $\beta$  induces blood-brain barrier disruption by downregulating Sonic hedgehog in astrocytes. *PLoS One* (2014) 9: e110024–e110024. doi: 10.1371/journal.pone.0110024

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

87. Patra A, Chen X, Sadowska GB, Zhang J, Lim Y-P, Padbury JF, et al. Neutralizing anti-interleukin-1 $\beta$  antibodies reduce ischemia-related interleukin-1 $\beta$  transport across the blood-brain barrier in fetal sheep. *Neuroscience* (2017) 346: 113–25. doi: 10.1016/j.neuroscience.2016.12.051

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

88. Didier N, Romero IA, Cr eminon C, Wijkhuisen A, Grassi J, Mabondzo A. Secretion of interleukin-1 $\beta$  by astrocytes mediates endothelin-1 and tumour necrosis factor- $\alpha$  effects on human brain microvascular endothelial cell permeability. *J Neurochem* (2003) 86: 246–54. doi: 10.1046/j.1471-4159.2003.01829.x

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

89. Han H, Mann A, Ekstein D, Eyal S. Breaking Bad: the Structure and Function of the Blood-Brain Barrier in Epilepsy. *AAPS J* (2017) 19: 973–88. doi: 10.1208/s12248-017-0096-2

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

90. Barr Taura L, Latour Lawrence L, Lee K-Y, Schaewe Timothy J, Luby M, Chang George S, et al. Blood-Brain Barrier Disruption in Humans Is Independently Associated With Increased Matrix Metalloproteinase-9. *Stroke* (2010) 41: e123-8. doi: 10. 1161/STROKEAHA. 109. 570515

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

91. Rüber T, David B, Lüchters G, Nass RD, Friedman A, Surges R, et al. Evidence for peri-ictal blood-brain barrier dysfunction in patients with epilepsy. *Brain* (2018) 141: 2952-65. doi: 10. 1093/brain/awy242

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

92. Rempe RG, Hartz AMS, Soldner ELB, Sokola BS, Alluri SR, Abner EL, et al. Matrix Metalloproteinase-Mediated Blood-Brain Barrier Dysfunction in Epilepsy. *J Neurosci : Off J Soc Neurosci* (2018) 38: 4301-15. doi: 10. 1523/JNEUROSCI. 2751-17. 2018

[CrossRef Full Text](#) | [Google Scholar](#)

93. Kho DT, Johnson RH, O'Carroll SJ, Angel CE, Graham ES. Biosensor Technology Reveals the Disruption of the Endothelial Barrier Function and the Subsequent Death of Blood Brain Barrier Endothelial Cells to Sodium Azide and Its Gaseous Products. *Biosensors* (2017) 7: 41. doi: 10. 3390/bios7040041

[CrossRef Full Text](#) | [Google Scholar](#)

94. Zuo X, Lu J, Manaenko A, Qi X, Tang J, Mei Q, et al. MicroRNA-132 attenuates cerebral injury by protecting blood-brain-barrier in MCAO mice. *Exp Neurol* (2019) 316: 12–9. doi: 10. 1016/j. expneurol. 2019. 03. 017

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

95. Zhao Z, Zlokovic BV. Remote control of BBB: A tale of exosomes and microRNA. *Cell Res* (2017) 27: 849–50. doi: 10. 1038/cr. 2017. 71

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

96. Ma T, Chen Y, Chen Y, Meng Q, Sun J, Shao L, et al. MicroRNA-132, Delivered by Mesenchymal Stem Cell-Derived Exosomes, Promote Angiogenesis in Myocardial Infarction. *Stem Cells Int* (2018) 2018: 3290372. doi: 10. 1155/2018/3290372

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

97. Simons M, Raposo G. Exosomes – vesicular carriers for intercellular communication. *Curr Opin Cell Biol* (2009) 21: 575–81. doi: 10. 1016/j. ceb. 2009. 03. 007

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

98. Hood JL. Post isolation modification of exosomes for nanomedicine applications. *Nanomed (London England)* (2016) 11: 1745–56. doi: 10. 2217/nnm-2016-0102

[CrossRef Full Text](#) | [Google Scholar](#)

99. Mathivanan S, Fahner CJ, Reid GE, Simpson RJ. ExoCarta 2012: database of exosomal proteins, RNA and lipids. *Nucleic Acids Res* (2012) 40: D1241-4. doi: 10.1093/nar/gkr828

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

100. Desrochers LM, Antonyak MA, Cerione RA. Extracellular Vesicles: Satellites of Information Transfer in Cancer and Stem Cell Biology. *Dev Cell* (2016) 37: 301-9. doi: 10.1016/j.devcel.2016.04.019

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

101. Bang C, Thum T. Exosomes: New players in cell-cell communication. *Int J Biochem Cell Biol* (2012) 44: 2060-4. doi: 10.1016/j.biocel.2012.08.007

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

102. Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, Sun D. Engineering exosomes as refined biological nanoplateforms for drug delivery. *Acta Pharmacol Sin* (2017) 38: 754-63. doi: 10.1038/aps.2017.12

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

103. Ohno S-i, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. *Mol Ther : J Am Soc Gene Ther* (2013) 21: 185-91. doi: 10.1038/mt.2012.180

[CrossRef Full Text](#) | [Google Scholar](#)

104. Vickers KC, Remaley AT. Lipid-based carriers of microRNAs and intercellular communication. *Curr Opin Lipidol* (2012) 23: 91–7. doi: 10.1097/MOL.0b013e328350a425

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

105. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nat Biotechnol* (2011) 29: 341–5. doi: 10.1038/nbt.1807

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

106. Kowal J, Tkach M, Théry C. Biogenesis and secretion of exosomes. *Curr Opin Cell Biol* (2014) 29: 116–25. doi: 10.1016/j.ceb.2014.05.004

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

107. Rashed M H, Bayraktar E K, Helal G, Abd-Ellah MF, Amero P, Chavez-Reyes A, et al. Exosomes: From Garbage Bins to Promising Therapeutic Targets. *Int J Mol Sci* (2017) 18: 538. doi: 10.3390/ijms18030538

[CrossRef Full Text](#) | [Google Scholar](#)

108. Li S-P, Lin Z-X, Jiang X-Y, Yu X-Y. Exosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools. *Acta Pharmacolog Sin* (2018) 39: 542–51. doi: 10.1038/aps.2017.178

[CrossRef Full Text](#) | [Google Scholar](#)



109. Xie F, Zhou X, Fang M, Li H, Su P, Tu Y, et al. Extracellular Vesicles in Cancer Immune Microenvironment and Cancer Immunotherapy. *Adv Sci (Weinh)* (2019) 6: 1901779. doi: 10. 1002/advs. 201901779

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)